697 related articles for article (PubMed ID: 24150772)
21. Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment.
Cekic C; Day YJ; Sag D; Linden J
Cancer Res; 2014 Dec; 74(24):7250-9. PubMed ID: 25377469
[TBL] [Abstract][Full Text] [Related]
22. Myeloid-derived suppressor cells infiltrate the heart in acute Trypanosoma cruzi infection.
Cuervo H; Guerrero NA; Carbajosa S; Beschin A; De Baetselier P; Gironès N; Fresno M
J Immunol; 2011 Sep; 187(5):2656-65. PubMed ID: 21804013
[TBL] [Abstract][Full Text] [Related]
23. Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment.
Lesokhin AM; Hohl TM; Kitano S; Cortez C; Hirschhorn-Cymerman D; Avogadri F; Rizzuto GA; Lazarus JJ; Pamer EG; Houghton AN; Merghoub T; Wolchok JD
Cancer Res; 2012 Feb; 72(4):876-86. PubMed ID: 22174368
[TBL] [Abstract][Full Text] [Related]
24. IL-33 inhibits the differentiation and immunosuppressive activity of granulocytic myeloid-derived suppressor cells in tumor-bearing mice.
Lim HX; Choi S; Cho D; Kim TS
Immunol Cell Biol; 2017 Jan; 95(1):99-107. PubMed ID: 27507556
[TBL] [Abstract][Full Text] [Related]
25. Immunosuppressive myeloid-derived suppressor cells can be converted into immunogenic APCs with the help of activated NKT cells: an alternative cell-based antitumor vaccine.
Ko HJ; Lee JM; Kim YJ; Kim YS; Lee KA; Kang CY
J Immunol; 2009 Feb; 182(4):1818-28. PubMed ID: 19201833
[TBL] [Abstract][Full Text] [Related]
26. Intratumoral injection of interferon-gamma gene-modified dendritic cells elicits potent antitumor effects: effective induction of tumor-specific CD8+ CTL response.
Pan J; Zhang M; Wang J; Wang Q; Xia D; Sun W; Zhang L; Yu H; Cao X
J Cancer Res Clin Oncol; 2005 Jul; 131(7):468-78. PubMed ID: 15711825
[TBL] [Abstract][Full Text] [Related]
27. Polysaccharide Agaricus blazei Murill stimulates myeloid derived suppressor cell differentiation from M2 to M1 type, which mediates inhibition of tumour immune-evasion via the Toll-like receptor 2 pathway.
Liu Y; Zhang L; Zhu X; Wang Y; Liu W; Gong W
Immunology; 2015 Nov; 146(3):379-91. PubMed ID: 26194418
[TBL] [Abstract][Full Text] [Related]
28. Mesenchymal stem cells tune the development of monocyte-derived dendritic cells toward a myeloid-derived suppressive phenotype through growth-regulated oncogene chemokines.
Chen HW; Chen HY; Wang LT; Wang FH; Fang LW; Lai HY; Chen HH; Lu J; Hung MS; Cheng Y; Chen MY; Liu SJ; Chong P; Lee OK; Hsu SC
J Immunol; 2013 May; 190(10):5065-77. PubMed ID: 23589610
[TBL] [Abstract][Full Text] [Related]
29. Myeloid-derived suppressor cells regulate T cell and B cell responses during autoimmune disease.
Crook KR; Jin M; Weeks MF; Rampersad RR; Baldi RM; Glekas AS; Shen Y; Esserman DA; Little P; Schwartz TA; Liu P
J Leukoc Biol; 2015 Mar; 97(3):573-82. PubMed ID: 25583578
[TBL] [Abstract][Full Text] [Related]
30. IL-18 enhances immunosuppressive responses by promoting differentiation into monocytic myeloid-derived suppressor cells.
Lim HX; Hong HJ; Cho D; Kim TS
J Immunol; 2014 Dec; 193(11):5453-60. PubMed ID: 25362180
[TBL] [Abstract][Full Text] [Related]
31. USP18 is crucial for IFN-γ-mediated inhibition of B16 melanoma tumorigenesis and antitumor immunity.
Hong B; Li H; Lu Y; Zhang M; Zheng Y; Qian J; Yi Q
Mol Cancer; 2014 May; 13():132. PubMed ID: 24884733
[TBL] [Abstract][Full Text] [Related]
32. Decreased tumor surveillance after adoptive T-cell therapy.
Matter M; Pavelic V; Pinschewer DD; Mumprecht S; Eschli B; Giroglou T; von Laer D; Ochsenbein AF
Cancer Res; 2007 Aug; 67(15):7467-76. PubMed ID: 17671217
[TBL] [Abstract][Full Text] [Related]
33. Effector cells derived from naive T cells used in tumor immunotherapy of mice bearing B16 melanoma.
Wen M; Xu W; Ren L; Gao F; Cui N; Wen J; Li X; Lin L; Ma Z; Chen B; Cai J
Chin Med J (Engl); 2014; 127(7):1328-33. PubMed ID: 24709189
[TBL] [Abstract][Full Text] [Related]
34. Enhanced suppressive capacity of tumor-infiltrating myeloid-derived suppressor cells compared with their peripheral counterparts.
Maenhout SK; Van Lint S; Emeagi PU; Thielemans K; Aerts JL
Int J Cancer; 2014 Mar; 134(5):1077-90. PubMed ID: 23983191
[TBL] [Abstract][Full Text] [Related]
35. Tumor-induced CD11b(+) Gr-1(+) myeloid-derived suppressor cells exacerbate immune-mediated hepatitis in mice in a CD40-dependent manner.
Kapanadze T; Medina-Echeverz J; Gamrekelashvili J; Weiss JM; Wiltrout RH; Kapoor V; Hawk N; Terabe M; Berzofsky JA; Manns MP; Wang E; Marincola FM; Korangy F; Greten TF
Eur J Immunol; 2015 Apr; 45(4):1148-58. PubMed ID: 25616156
[TBL] [Abstract][Full Text] [Related]
36. Macrophages are more potent immune suppressors ex vivo than immature myeloid-derived suppressor cells induced by metastatic murine mammary carcinomas.
Hamilton MJ; Bosiljcic M; Lepard NE; Halvorsen EC; Ho VW; Banáth JP; Krystal G; Bennewith KL
J Immunol; 2014 Jan; 192(1):512-22. PubMed ID: 24285836
[TBL] [Abstract][Full Text] [Related]
37. Cytotoxic T lymphocytes block tumor growth both by lytic activity and IFNγ-dependent cell-cycle arrest.
Matsushita H; Hosoi A; Ueha S; Abe J; Fujieda N; Tomura M; Maekawa R; Matsushima K; Ohara O; Kakimi K
Cancer Immunol Res; 2015 Jan; 3(1):26-36. PubMed ID: 25127875
[TBL] [Abstract][Full Text] [Related]
38. Dopamine inhibits the function of Gr-1+CD115+ myeloid-derived suppressor cells through D1-like receptors and enhances anti-tumor immunity.
Wu J; Zhang R; Tang N; Gong Z; Zhou J; Chen Y; Chen K; Cai W
J Leukoc Biol; 2015 Jan; 97(1):191-200. PubMed ID: 25341727
[TBL] [Abstract][Full Text] [Related]
39. Tumor conditions induce bone marrow expansion of granulocytic, but not monocytic, immunosuppressive leukocytes with increased CXCR2 expression in mice.
Bian Z; Shi L; Venkataramani M; Abdelaal AM; Culpepper C; Kidder K; Liang H; Zen K; Liu Y
Eur J Immunol; 2018 Mar; 48(3):532-542. PubMed ID: 29120053
[TBL] [Abstract][Full Text] [Related]
40. Combined dendritic cell cryotherapy of tumor induces systemic antimetastatic immunity.
Machlenkin A; Goldberger O; Tirosh B; Paz A; Volovitz I; Bar-Haim E; Lee SH; Vadai E; Tzehoval E; Eisenbach L
Clin Cancer Res; 2005 Jul; 11(13):4955-61. PubMed ID: 16000595
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
